OA12159A - Monohydrate of cis-lithium-cyano-4-Ä3-(cyclopentyloxy)-4-methoxyphenylÜcyclohexanecar-boxylate. - Google Patents

Monohydrate of cis-lithium-cyano-4-Ä3-(cyclopentyloxy)-4-methoxyphenylÜcyclohexanecar-boxylate. Download PDF

Info

Publication number
OA12159A
OA12159A OA1200200211A OA1200200211A OA12159A OA 12159 A OA12159 A OA 12159A OA 1200200211 A OA1200200211 A OA 1200200211A OA 1200200211 A OA1200200211 A OA 1200200211A OA 12159 A OA12159 A OA 12159A
Authority
OA
OAPI
Prior art keywords
monohydrate
cyclopentyloxy
cyano
lithium
cis
Prior art date
Application number
OA1200200211A
Other languages
English (en)
Inventor
Kevin Scott Webb
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of OA12159A publication Critical patent/OA12159A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/50—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
OA1200200211A 2000-01-26 2001-01-18 Monohydrate of cis-lithium-cyano-4-Ä3-(cyclopentyloxy)-4-methoxyphenylÜcyclohexanecar-boxylate. OA12159A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17812900P 2000-01-26 2000-01-26

Publications (1)

Publication Number Publication Date
OA12159A true OA12159A (en) 2006-05-08

Family

ID=22651319

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200200211A OA12159A (en) 2000-01-26 2001-01-18 Monohydrate of cis-lithium-cyano-4-Ä3-(cyclopentyloxy)-4-methoxyphenylÜcyclohexanecar-boxylate.

Country Status (36)

Country Link
US (1) US6699903B2 (zh)
EP (1) EP1250313B1 (zh)
JP (1) JP2003520842A (zh)
KR (1) KR20020073183A (zh)
CN (1) CN1157371C (zh)
AP (1) AP1432A (zh)
AR (1) AR027273A1 (zh)
AT (1) ATE344235T1 (zh)
AU (1) AU3282201A (zh)
BG (1) BG106959A (zh)
BR (1) BR0107709A (zh)
CA (1) CA2397758A1 (zh)
CO (1) CO5300517A1 (zh)
CY (1) CY1108515T1 (zh)
CZ (1) CZ20022590A3 (zh)
DE (1) DE60124221T2 (zh)
DK (1) DK1250313T3 (zh)
DZ (1) DZ3285A1 (zh)
EA (1) EA200200791A1 (zh)
EG (1) EG24065A (zh)
ES (1) ES2273804T3 (zh)
HK (1) HK1051030A1 (zh)
HU (1) HUP0204150A3 (zh)
IL (1) IL150400A0 (zh)
MA (1) MA25652A1 (zh)
MX (1) MXPA02007300A (zh)
MY (1) MY122802A (zh)
NO (1) NO20023378L (zh)
NZ (1) NZ519799A (zh)
OA (1) OA12159A (zh)
PE (1) PE20011040A1 (zh)
PL (1) PL356832A1 (zh)
PT (1) PT1250313E (zh)
SK (1) SK10942002A3 (zh)
WO (1) WO2001055094A1 (zh)
ZA (1) ZA200205925B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011802D0 (en) * 2000-05-16 2000-07-05 Smithkline Beecham Method for enhancing cognitive function

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552438A (en) 1992-04-02 1996-09-03 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
UA67753C2 (uk) * 1997-10-10 2004-07-15 Смітклайн Бічам Корпорейшн Спосіб отримання заміщених 4-феніл-4-ціанциклогексанових кислот

Also Published As

Publication number Publication date
CY1108515T1 (el) 2014-04-09
EP1250313A4 (en) 2005-09-21
HUP0204150A2 (hu) 2003-04-28
HK1051030A1 (zh) 2003-07-18
MA25652A1 (fr) 2002-12-31
CN1395556A (zh) 2003-02-05
AU3282201A (en) 2001-08-07
WO2001055094A1 (en) 2001-08-02
US20030032670A1 (en) 2003-02-13
EG24065A (en) 2008-05-08
CZ20022590A3 (cs) 2003-01-15
DK1250313T3 (da) 2007-02-12
NO20023378D0 (no) 2002-07-12
BR0107709A (pt) 2002-11-19
JP2003520842A (ja) 2003-07-08
ZA200205925B (en) 2003-11-21
MY122802A (en) 2006-05-31
DZ3285A1 (fr) 2001-08-02
PE20011040A1 (es) 2001-10-31
AR027273A1 (es) 2003-03-19
ATE344235T1 (de) 2006-11-15
EP1250313B1 (en) 2006-11-02
ES2273804T3 (es) 2007-05-16
DE60124221T2 (de) 2007-09-13
KR20020073183A (ko) 2002-09-19
AP1432A (en) 2005-06-20
CO5300517A1 (es) 2003-07-31
CA2397758A1 (en) 2001-08-02
EA200200791A1 (ru) 2002-12-26
PL356832A1 (en) 2004-07-12
NZ519799A (en) 2004-04-30
AP2002002566A0 (en) 2002-06-30
CN1157371C (zh) 2004-07-14
US6699903B2 (en) 2004-03-02
PT1250313E (pt) 2007-01-31
DE60124221D1 (de) 2006-12-14
BG106959A (en) 2003-05-30
IL150400A0 (en) 2002-12-01
MXPA02007300A (es) 2002-11-29
NO20023378L (no) 2002-07-12
HUP0204150A3 (en) 2003-05-28
SK10942002A3 (sk) 2002-11-06
EP1250313A1 (en) 2002-10-23

Similar Documents

Publication Publication Date Title
DE60308040T2 (de) Herstellung von 1H-Imidazo-4,5-C]-Chinolin-4-Aminen Ber 1H-Imidazo-4,5-C]-Chinolin-4-Phthalimid-Zwischenprodukten
US6562861B1 (en) Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
JP2002522541A (ja) ホスホジエステラーゼ４阻害剤としての置換１，８−ナフチリジン−４（１ｈ）−オン
US20050239823A1 (en) Substituted C-imidazo[1,2-a]pyridin-3yl-methylamines
CA2975260A1 (en) Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
CZ292427B6 (cs) Způsob výroby enanciomerů O-demethyltramadolu
EP3750889B1 (en) Memantine paroxetine cocrystal salt and its preparation method, pharmaceutical composition and application
OA12159A (en) Monohydrate of cis-lithium-cyano-4-Ä3-(cyclopentyloxy)-4-methoxyphenylÜcyclohexanecar-boxylate.
JP2008526803A (ja) Ｃｎｓ障害、痛み、発作、中毒およびてんかんの治療に用いるための置換２‐アミノ‐キナゾリン４‐ｃｎ化合物、その調製、並びに中間生成物としてのその使用
US20040122044A1 (en) Utilization of substituted imidazo [1,2-A]-pyridin-3-yl-amide and imidazo [1,2-A]-pyridin-3-yl-amine compounds in pharmaceutical formulations
EP0552138B1 (en) Use of esters of acyl carnitines with long-chain aliphatic alcohols in the preparation of pharmaceutical compositions having antimycotic activity
CN113121417A (zh) 一种新型哌啶衍生物及其药物用途
CA2997541C (en) Therapeutic compounds for pain and synthesis thereof
US9650332B1 (en) Prodrug of probucol and method for preparing the same
CN116283946B (zh) 5-(n-取代吲哚-5-基)异噁唑-3-甲酸衍生物及其合成方法和应用
CN106083844B (zh) 一种制备抗乳腺癌药物帕博西尼中间体的方法
JPH03145492A (ja) ピロロキノリンキノンエステル
CN118619921A (zh) 含吡咯烷酮结构的化合物
CN115340510A (zh) 一种布立西坦中间体制备方法
AU2003212040C1 (en) Substituted Cyclopentane And Cyclopentene Compounds Useful As Neuraminidase Inhibitors
CN111333635A (zh) 一种利伐沙班杂质对照品及其制备方法
Buchbauer et al. 2D-NMR, 6. Mitt.: 2D-INADEQUATE Spektrum und Kristallstruktur von einem Tricyclo [7.3. 1.0 2, 7] tridecanderivat
JPS63280054A (ja) 活性化ニトロソカルバメートの製造方法
CN102234255A (zh) 2-吗啉基异嵌烷-10-硫醇的制备方法及其所形成的中间物